Eun Jeong Min, Soo Hyun Lee, Joo-Young Jo, Jong Gyun Ahn, Dae Chul Jeong
{"title":"使用国家索赔数据对青少年特发性关节炎患者疾病模式进行基于人群的大数据分析。","authors":"Eun Jeong Min, Soo Hyun Lee, Joo-Young Jo, Jong Gyun Ahn, Dae Chul Jeong","doi":"10.3346/jkms.2025.40.e113","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to identify epidemiologic data, including prevalence and incidence, of patients with juvenile idiopathic arthritis (JIA) in accordance with the diseases diagnostic code and Rare Intractable Disease Registration (RIDR) code from the claims data of the Health Insurance Review and Assessment Service (HIRA), the representative secondary data in Korea.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of the national claims data of the HIRA. The study population included 1,728 patients with JIA who 1) had records with diagnostic codes in the format prescribed by the International Classification of Diseases, 10th Revision M08 and the RIDR code V133 between January 1, 2010, and December 31, 2019, and 2) were aged < 16 years as per the definition of JIA. We categorized the patients by age at diagnosis, annual prevalence, and incidence per 100,000 individuals for the study period. Moreover, the study population was stratified by age and gender for subgroup analysis.</p><p><strong>Results: </strong>The overall prevalence rate for the total, male, and female population was 15.9 (14.5-16.8), 15.4 (13.1-17.0), and 16.4 (15.9-16.9) per 100,000 individuals, respectively. Additionally, the overall incidence rate for the same populations was 2.2 (1.8-2.8), 2.3 (1.7-2.9), and 2.1 (1.8-2.6) per 100,000 individuals, respectively.</p><p><strong>Conclusion: </strong>To the best of our knowledge, this is the first study presenting the epidemiologic data, including prevalence and incidence, of patients with JIA using population-based claims big data in Korea. The results of this study will aid in understanding the current status of JIA in Korea and Asia and in health care planning.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":"40 22","pages":"e113"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148553/pdf/","citationCount":"0","resultStr":"{\"title\":\"Population-Based Big Data Analysis on Disease Patterns in Patients Identified With Juvenile Idiopathic Arthritis Using National Claims Data.\",\"authors\":\"Eun Jeong Min, Soo Hyun Lee, Joo-Young Jo, Jong Gyun Ahn, Dae Chul Jeong\",\"doi\":\"10.3346/jkms.2025.40.e113\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This study aimed to identify epidemiologic data, including prevalence and incidence, of patients with juvenile idiopathic arthritis (JIA) in accordance with the diseases diagnostic code and Rare Intractable Disease Registration (RIDR) code from the claims data of the Health Insurance Review and Assessment Service (HIRA), the representative secondary data in Korea.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of the national claims data of the HIRA. The study population included 1,728 patients with JIA who 1) had records with diagnostic codes in the format prescribed by the International Classification of Diseases, 10th Revision M08 and the RIDR code V133 between January 1, 2010, and December 31, 2019, and 2) were aged < 16 years as per the definition of JIA. We categorized the patients by age at diagnosis, annual prevalence, and incidence per 100,000 individuals for the study period. Moreover, the study population was stratified by age and gender for subgroup analysis.</p><p><strong>Results: </strong>The overall prevalence rate for the total, male, and female population was 15.9 (14.5-16.8), 15.4 (13.1-17.0), and 16.4 (15.9-16.9) per 100,000 individuals, respectively. Additionally, the overall incidence rate for the same populations was 2.2 (1.8-2.8), 2.3 (1.7-2.9), and 2.1 (1.8-2.6) per 100,000 individuals, respectively.</p><p><strong>Conclusion: </strong>To the best of our knowledge, this is the first study presenting the epidemiologic data, including prevalence and incidence, of patients with JIA using population-based claims big data in Korea. The results of this study will aid in understanding the current status of JIA in Korea and Asia and in health care planning.</p>\",\"PeriodicalId\":16249,\"journal\":{\"name\":\"Journal of Korean Medical Science\",\"volume\":\"40 22\",\"pages\":\"e113\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148553/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Korean Medical Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3346/jkms.2025.40.e113\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Korean Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3346/jkms.2025.40.e113","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Population-Based Big Data Analysis on Disease Patterns in Patients Identified With Juvenile Idiopathic Arthritis Using National Claims Data.
Background: This study aimed to identify epidemiologic data, including prevalence and incidence, of patients with juvenile idiopathic arthritis (JIA) in accordance with the diseases diagnostic code and Rare Intractable Disease Registration (RIDR) code from the claims data of the Health Insurance Review and Assessment Service (HIRA), the representative secondary data in Korea.
Methods: We conducted a retrospective analysis of the national claims data of the HIRA. The study population included 1,728 patients with JIA who 1) had records with diagnostic codes in the format prescribed by the International Classification of Diseases, 10th Revision M08 and the RIDR code V133 between January 1, 2010, and December 31, 2019, and 2) were aged < 16 years as per the definition of JIA. We categorized the patients by age at diagnosis, annual prevalence, and incidence per 100,000 individuals for the study period. Moreover, the study population was stratified by age and gender for subgroup analysis.
Results: The overall prevalence rate for the total, male, and female population was 15.9 (14.5-16.8), 15.4 (13.1-17.0), and 16.4 (15.9-16.9) per 100,000 individuals, respectively. Additionally, the overall incidence rate for the same populations was 2.2 (1.8-2.8), 2.3 (1.7-2.9), and 2.1 (1.8-2.6) per 100,000 individuals, respectively.
Conclusion: To the best of our knowledge, this is the first study presenting the epidemiologic data, including prevalence and incidence, of patients with JIA using population-based claims big data in Korea. The results of this study will aid in understanding the current status of JIA in Korea and Asia and in health care planning.
期刊介绍:
The Journal of Korean Medical Science (JKMS) is an international, peer-reviewed Open Access journal of medicine published weekly in English. The Journal’s publisher is the Korean Academy of Medical Sciences (KAMS), Korean Medical Association (KMA). JKMS aims to publish evidence-based, scientific research articles from various disciplines of the medical sciences. The Journal welcomes articles of general interest to medical researchers especially when they contain original information. Articles on the clinical evaluation of drugs and other therapies, epidemiologic studies of the general population, studies on pathogenic organisms and toxic materials, and the toxicities and adverse effects of therapeutics are welcome.